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Methods
We used data from 35 914 women in the Danish National Birth Cohort who at recruitment had reported the number of weeks of supplement use during a 12-week periconceptional period. A telephone interview provided information about maternal characteristics and data on fetal death came from registers. The associations between periconceptional multivitamin or folate-only use and early (<20 weeks) and late (520 weeks) fetal death were estimated by hazard ratios (HR) with 95% confidence intervals (CI). Follow-up started at 8 completed weeks of gestation, and comparisons were made with no supplement use at any time during the periconceptional period. 
Results
Any
Introduction
Conception, implantation and early development of the fetus and placenta require energy and micronutrients, including vitamins, [1] [2] [3] [4] [5] but the optimal doses and combinations are still largely unknown. Previous studies of periconceptional use of multivitamins in well-nourished women indicate a beneficial effect on the incidence of preeclampsia, 6, 7 intrauterine growth restriction and preterm birth, 8, 9 possibly operating by affecting the early development and function of the placenta. [10] [11] [12] If so, it may be hypothesized that periconceptional use of multivitamins also lowers the risk of late fetal death, [13] [14] [15] [16] [17] as several studies indicate that late fetal death shares a common underlying aetiology related to early placental dysfunction with these outcomes. 15, [17] [18] [19] Supplementation with folate, either as a single supplement or included in a multivitamin product, is recommended before and early in pregnancy, mainly because the protective effect on neural tube defects is believed to require more folate than is provided by a prudent diet. [20] [21] [22] However, justification of periconceptional multivitamin use is still controversial, partly due to the possible increased risk of twinning. 23, 24 Also, some studies, 25, 26 but not all, 27, 28 indicate a modest increased risk of fetal death after periconceptional multivitamin use which seems unrelated to the content of folate. 29, 30 A Cochrane review stated that multivitamin use during pregnancy was not associated with either increased or decreased risk of fetal death, 23 but only few included studies allowed assessment of periconceptional use and the power to evaluate stillbirth risk was low.
Several studies in the general population have shown that supplements of vitamins in well-nourished people may increase the risk of cancer [31] [32] [33] and overall mortality. [33] [34] [35] Nevertheless, women are advised to take multivitamins when they plan to conceive, believing it can do no harm. It is therefore of importance to estimate any effects of early multivitamins on the entire range of pregnancy outcomes. We used data from the Danish National Birth Cohort (DNBC) to examine the association between periconceptional multivitamin or folate-only use and risk of early and late fetal death, accounting for timing of use and important maternal factors.
Methods
Study population
The DNBC is a nationwide study of 100 419 pregnancies among 92 374 women recruited in 1996-2002. In the second round of enrolment, women completed a revised version of the recruitment form where they were asked about supplement use week by week (45 040 pregnancies). Women with an uncertain recruitment date or who joined the cohort before 5 weeks of gestation were excluded (n ¼ 505) as were women with unknown pregnancy outcome (n ¼ 9).Women who reported only single supplement use (other than folate) or did not report weeks of use were also excluded (n ¼ 8550). Finally, we excluded 64 pregnancies that were aborted before follow-up started at 8 completed weeks of gestation. The final study population consisted of 35 914 pregnancies among 35 172 women.
Measures
The recruitment form was returned at approximately 11 weeks of gestation (interquartile range 9-14 weeks). It provided a form with week by week boxes to report supplement use by type and frequency from 4 weeks before the last menstrual period (LMP) through 14 weeks after the LMP. We defined the periconceptional period in weeks as LMP-4 through LMP þ 8, and this period was further categorized as a 6-week preconception period (LMP-4 to LMP þ 2) and a 6-week postconception period (LMP þ 3 to LMP þ 8) (Figure 1 ). For the 3308 women recruited during gestation weeks 5, 6 and 7, we imputed supplement use for the remainder of the periconceptional period based on use reported during the week of enrolment. The contents of the most commonly used multivitamin use in the study period are provided in Table 1 . The recommendations regarding folate-only use was 400 lg/day.
Use of multivitamins was defined as any use in each of the 12 weeks comprising the peri-conceptional period. We also computed duration of multivitamin use for the pre-and post-conception periods as the reported number of weeks of use, which was categorized into non-users and users in 1-2 weeks, 3-4 weeks, and 5-6 weeks relative to the 6 weeks comprising each of these periods. Finally, we defined women with different patterns of multivitamin use based on either no use, partial use (1-3 weeks) or regular use (4-6 weeks) in either the pre or post-conception period. This led to the following categories (pre/post use): regular/regular; partial/regular; no/ regular; no or partial/no or partial; no/no (reference). For folate-only users, we generated the same variables.
A fetal death was defined as a non-deliberate demise of an intrauterine pregnancy and included spontaneous abortions and stillbirths leading to hospital admission. These were identified together with live births, induced abortions, ectopic pregnancies and hydatidiform mole by linking the Civil Registration Register, the National Birth Register and the National Hospital Discharge Register using the mother's civil registration number. The estimate of gestational age was based on the LMP as reported by the woman at recruitment and was validated in case of unlikely estimates. At recruitment, women agreed to participate in four telephone interviews. The first took place at approximately 17 weeks of gestation (interquartile range 14-21 weeks), and it was possible to reach 92.5% of the women in the present study. If the woman was no longer pregnant, she was offered a slightly modified interview, which was accepted by 766 women. From these two interviews, we defined pregnancyrelated covariates including parity, previous miscarriages, waiting time to pregnancy, use of infertility treatment, prepregnancy body mass index (BMI, kg/m 2 ), smoking and social status ( Table 2) . A second interview at approximately 30 weeks of gestation provided information about nausea in the first 8 weeks of pregnancy, and from 185 women with fetal death (mainly late) we had the same information reported retrospectively. For women who were still pregnant in mid-pregnancy, including 87 with late fetal death, dietary data were available from a mail-distributed and validated food frequency questionnaire. 36 Diet was characterized as 'Western' (high-fat dairy and red meat), 'health conscious' (intake of fruits and vegetables, poultry and fish) and 'intermediate' as previously reported. 37 
Statistical analysis
To illustrate risk of fetal death over duration of gestation, we first calculated rates of fetal death according to use of multivitamins and folate-only supplements for the following periods: 8-11 weeks, 12-19 weeks, 20-27 weeks and 28 weeksþ. Followup started at gestational day 56 (8 completed weeks) and ended at the time of fetal death, live birth, induced abortion, hydatidiform mole or emigration. Multiple pregnancies (n ¼ 766) were coded as live births if all (n ¼ 761) or just one (n ¼ 5) baby were born alive.
The risk of fetal death associated with any periconceptional multivitamin or folate-only use was estimated as hazard ratios with 95% confidence intervals using Cox regression with gestational days as the underlying time variable. When fetal death was divided into an early and late period at 520 completed weeks of gestation, which is in accord with the threshold used in other studies, 23 we found interaction between any multivitamin use and gestational age(crude analysis; P interaction ¼ 0.02). In some models we therefore included an interaction term to present estimates for early fetal deaths (<20 weeks) and late fetal death (520 completed weeks) separately. Based on previous studies, 7, 9 we also examined for interaction by maternal weight (BMI 525), but this was not found. We also evaluated the duration and timing of multivitamin use by entering pre-and post-conception use as categorical exposure variables, which were mutually adjusted to account for the fact that most women with preconception use were also users in the postconception period. Next, we used the exposure variable for different patterns of multivitamin use. Non-users at any time were the referent for all models. These analyses were also carried out for folate-only use.
In adjusted analyses, we controlled for age, parity, prepregnancy BMI, smoking and social status. Because women with fertility problems or previous miscarriage may more often be early multivitamin users, we also adjusted for waiting time to pregnancy, infertility treatment and previous miscarriage.
In supplementary analyses, we restricted the analyses to nulliparous women with spontaneous pregnancies, a waiting time to pregnancy <6 months and no previous miscarriage. We also repeated all analyses after excluding 5024 pregnancies among multivitamin users where intake of single supplements other than folate was reported. Finally, we added adjustment for nausea and mid-pregnancy diet and restricted the analysis to women with prospectively collected information about confounders. We used a correction for within-cluster correlation (robust standard errors) since 742 women contributed more than one pregnancy to the study. STATA 9.1 Special Edition (Stata Corporation, College Station, TX) was used for all statistical analyses.
Results
Overall, any multivitamin use was reported in 22 285 pregnancies (62.1%), folate-only supplementation in 2236 pregnancies (6.2%) and in 11 393 pregnancies (31.7%) no use of multivitamins, folate-only or any other single supplementation was reported during the periconceptional period (Table 2) . Compared with non-users, multivitamin and folate-only users were more likely to be nulliparous, 25-35 years old and to have lower BMI. They reported more often planned pregnancies, a longer waiting time to pregnancy, more frequent use of infertility treatment and a history of miscarriage. They were less likely to smoke and to be of lower social status. Nausea in the first 8 weeks of pregnancy was more common among multivitamin and folate-only users who were also more likely to report a diet classified as health conscious. They had more multiple births, but not when infertility-treated women were excluded (1.20% in non-users, 1.26% in multivitamin users and 1.04% in folate-only users). We observed 1552 fetal deaths in the study population [1346 early (<20 weeks) and 206 late (520 weeks)]. Rates of fetal death decreased steeply across gestation from 49.8 per 10 000 weeks in weeks 8-11, 22.9 in weeks 12-19, 3.3 in weeks 20-27 and 2.8 from week 28 onwards (Figure 2) . Compared with non-users, multivitamin users had higher rates before 20 weeks of gestation and lower rates thereafter, but with overlapping confidence intervals in the late period. Fetal death rates for folate-only users did not provide any clear pattern and was omitted from the figure.
For the entire period, multivitamin use was associated with a 12% increased crude risk of fetal death, restricted to early losses before 20 weeks of gestation [HR 1.18 (1.05-1.33)] as compared with losses thereafter [HR 0.82 (0.62-1.10), P interaction ¼ 0.02] ( Table 3 ). In the analysis restricted to women with confounder information, the crude risk of fetal death in multivitamin users was slightly higher than in the full sample, and this excess risk increased further after adjustment. The association between multivitamin use and late fetal death seemed slightly stronger in lean women [HR 0.79 (0.52-1.18)] and not present in overweight women [HR 1.17 (0.71-1.94)] with a ratio of hazard ratios of 1.49 (P ¼ 0.23). Thus, we had restricted power to examine this issue. Folate-only users had no excess risk at any time, but associations were estimated with large imprecision.
To examine the robustness of these findings, we repeated the analysis after excluding multivitamin users with single supplement use other than folate (n ¼ 5024).This decreased the risk of fetal death slightly [crude HRs 1.10 (0.98-1.23) for all fetal death; 1.15 (1.00-1.30) and 0.85 (0.63-1.15) for In the group of multivitamin users (62.1%), the following patterns of use were observed. Regular multivitamin use throughout the entire period was reported by 24.5%, 6.6% reported partial use before conception followed by regular post-conception use and 12.2% had no use before conception followed by regular use. Finally, 18.8% reported some combination of no use/ partial use during the two periods. Compared with women with no use, only regular use throughout the periconceptional period was associated with increased risk of early fetal death [crude HR 1.29 (1.12-1.48)] (Table 5 ). For late fetal death, especially women where regular multivitamin use was initiated after conception, seemed to have reduced risks of about 35-60%, but number of deaths was small. Again, adjustment had only minor effect on the crude estimates.
When the above analyses of duration and pattern of use were repeated in the much smaller sample of folate-only users compared with non-users, hazard ratios were estimated with large imprecision and no clear pattern (results available on request).
Discussion
We found a modest but consistent increased risk of early fetal death in multivitamin users, especially in women with a regular preconceptional intake. For late fetal death, we observed some indication of a beneficial effect of multivitamin use in women with regular use after conception, but interpretation should be made with caution due to the few cases in these analyses. Folate-only use was not associated with fetal death, but our ability to examine this exposure was limited by a relatively small number of users. The increased risk of fetal death in multivitamin users corroborates results from two other studies from affluent countries where periconceptional multivitamin use was associated with a modest increased risk of about 15% in interventional 38, 39 and observational designs. 26 Also, the excess risk was slightly higher for use that started prior to pregnancy rather than in pregnancy. 26 Another randomized trial in women with previous neural tube defects pregnancies showed no increased risk, 40, 41 but all studies were based on relatively small numbers and results were controversial. 30, 42, 43 A Cochrane review from 2011 reported pooled estimates close to one for the association between periconceptional multivitamin use and both early and late fetal death. 23 It included the two randomized studies mentioned above 37, 39 and a small trial from India. 44 Other studies, based on observational data, reported 40-60% decreased risks of early fetal death in multivitamin users, 27, 28 but findings may well be biased by selection problems and differential recall of use and confounded by healthy behaviours and practices in this group. As expected, we found multivitamin users to be better educated and have healthier diets and lifestyles, all factors that may explain a decreased risk of late fetal death as well as the decreased risks of preeclampsia, small-for-gestational-age (SGA) and preterm birth that we have observed in the same cohort. 7, 9 However, any uncontrolled confounding of this type cannot explain the observed increased risk of early fetal death. Confounding may be present if very health conscious women with low early weight gain and excessive physical activity or with some kind of morbidity related to poor fetal health more often took multivitamins or folate. We do not think this is the case; on the contrary we found that women with nausea, which is a marker of a healthy pregnancy, 45, 46 were more often multivitamin users. Only when nausea leads to a very poor diet, which is rare, this might be a problem. Users did more frequently report fertility problems and previous miscarriages, which are associated with increased risk of fetal death, but accounting for these factors did not change the results. It has been suggested that more multiple pregnancies in multivitamin users may explain the excess risk of fetal death. 47 Regrettably, we were not able to identify multiple pregnancies in fetal deaths before 28 weeks of gestation. In women with spontaneous pregnancies,we did not find multivitamin users to have more multiple births, but this does not exclude the possibility that they may have had more multiple pregnancies ending as spontaneous abortions. Some multivitamin users reported use of single supplements within the periconceptional window, typically before they started regular intake of multivitamins. Excluding these women from the analyses had no effect on the estimates either. We ran out of suggestions for confounding factors that may explain the observed association, and our ability to examine those we identified was not always optimal.
Information about use of supplements was provided by the women themselves, but reported prospectively Use in the 6-week interval: À (no use); þ (1 to 3 weeks; partial use); þþ (4-6 weeks; regular use).
PERICONCEPTIONAL INTAKE OF MULTIVITAMINS AND FETAL DEATH
before the event under study. For some women, we extrapolated information on use from recruitment to the rest of the periconceptional window, but excluding these pregnancies from the analyses did not change the results. Information about most confounders was provided retrospectively for 74% of women with fetal death. We restricted the adjusted analyses to women with prospectively collected information and had similar effects on the crude estimates, indicating that differential recall of confounders was not a problem.
Selection bias of the adjusted estimates should be considered if multivitamin users with fetal death were more willing to participate in the interview than users with a live birth. We did observe a slight tendency in this direction, leading to a positive bias of 5% which means that the adjusted excess risk in multivitamin users should rather be 17% than 23%. For this reason, we chose to focus mainly on the crude estimates derived from the main study population although they may be slightly underestimated. We had close to complete follow-up, but regrettably no information about very early abortions. If multivitamin use delays the termination of less viable fetuses, this would lead to an apparent excess risk of fetal death after 8 weeks of gestation as observed in our study. However, we find this phenomenon less likely.
Although the excess risk of early fetal death that we observed may come with a decreased risk of more rare deaths later in pregnancy, the finding causes concern. With the available data, we were not able to explain why use of multivitamins, especially when taken in the preconception period, should increase risk of early fetal death. Adverse pregnancy outcomes have been observed with large doses of vitamins and other micronutrients, 48 especially vitamin A in early gestation, 49 but the concentration of these constituents is much lower in multivitamins. Apart from a decreased risk of low birthweight in multivitamin users, there is no convincing evidence from randomized trials of a beneficial effect on pregnancy outcomes. 50 Our findings are based on observational data and need replication, especially in lower socio-economic groups, but they highlight the lack of evidence for periconceptional multivitamin use on risk of miscarriage and stillbirth. 23 It is, on the other hand, important to stress that this study does not provide evidence against use of folate supplements to reduce risk of neural tube defects and it is insufficient to change recommendations regarding multivitamins containg folate. Randomized trials and large observational studies, preferably preconceptional cohorts from different settings, are needed to guide public health recommendations. 
KEY MESSAGES
Periconceptional multivitamin use (6 weeks before and 6 weeks after conception) has been associated with lower incidence of preeclampsia, of growth restriction and of preterm birth; however, there is evidence indicating a modest increased risk of fetal death after periconceptional multivitamin use.
Using data from the Danish National Birth Cohort we related the timing and duration of periconceptional multivitamin use to risk of early and late fetal death.
Regular periconceptional multivitamin use was associated with a modest increased risk of early fetal death (<20 weeks), but regular use after conception may decrease risk for late fetal death (420 weeks).
These findings are based on observational data, but highlight the lack of evidence for periconceptional multivitamin use on risk of miscarriage.
It is important to stress that this study does not affect the recommendations to use folate supplements, either alone or in combination with multivitamins, to reduce risk of neural tube defects.
